Trial · NCT03385239
Results by group84
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 84
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point | Pooled Placebo | 6 | 95% Confidence Interval -9 to 23 | percent change | |
| Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point | Cohort A: ISIS 678354: 10 mg Q4W | -23 | 95% Confidence Interval -34 to -10 | percent change | |
| Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point | Cohort C: ISIS 678354: 15 mg Q2W | -56 | 95% Confidence Interval -62 to -49 | percent change | |
| Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point | Cohort D: ISIS 678354: 10 mg QW | -60 | 95% Confidence Interval -66 to -54 | percent change | |
| Percent Change From Baseline in Fasting Triglycerides (TG) at the Primary Analysis Time Point | Cohort B: ISIS 678354: 50 mg Q4W | -60 | 95% Confidence Interval -65 to -53 | percent change | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Pooled Placebo | 20 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort A: ISIS 678354: 10 mg Q4W | 17 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort C: ISIS 678354: 15 mg Q2W | 20 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort D: ISIS 678354: 10 mg QW | 22 | Participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Cohort B: ISIS 678354: 50 mg Q4W | 21 | Participants | ||
| Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point | Pooled Placebo | Apo-C III | 2 | 95% Confidence Interval -16 to 23 | percent change |
| Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point | Cohort A: ISIS 678354: 10 mg Q4W | Apo-C III | -29 | 95% Confidence Interval -42 to -13 | percent change |
| Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point | Cohort C: ISIS 678354: 15 mg Q2W | Apo-C III | -68 | 95% Confidence Interval -74 to -61 | percent change |
| Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point | Cohort D: ISIS 678354: 10 mg QW | Apo-C III | -73 | 95% Confidence Interval -78 to -67 | percent change |
| Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point | Cohort B: ISIS 678354: 50 mg Q4W | Apo-C III | -74 | 95% Confidence Interval -78 to -69 | percent change |
| Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point | Pooled Placebo | TC | 1 | 95% Confidence Interval -6 to 7 | percent change |
| Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point | Cohort A: ISIS 678354: 10 mg Q4W | TC | -2 | 95% Confidence Interval -8 to 5 | percent change |
| Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point | Cohort C: ISIS 678354: 15 mg Q2W | TC | -12 | 95% Confidence Interval -17 to -5 | percent change |
| Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point | Cohort D: ISIS 678354: 10 mg QW | TC | -3 | 95% Confidence Interval -9 to 4 | percent change |
| Percent Change From Baseline in ApoC-III, TC, LDL-C, HDL-C, Non-HDL-C, VLDL-C, ApoB, and ApoA-I at the Primary Analysis Time Point | Cohort B: ISIS 678354: 50 mg Q4W | TC | -8 | 95% Confidence Interval -13 to -2 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03385239/results